Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It… Read more
Ryvu Therapeutics SA (RVU) - Total Liabilities
Latest total liabilities as of September 2025: zł184.12 Million PLN
Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has total liabilities worth zł184.12 Million PLN as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ryvu Therapeutics SA - Total Liabilities Trend (2010–2024)
This chart illustrates how Ryvu Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ryvu Therapeutics SA Competitors by Total Liabilities
The table below lists competitors of Ryvu Therapeutics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Real Estate Investment Trust of New Jersey Inc
PINK:FREVS
|
USA | $124.17 Million |
|
HKScan Oyj Series A
LSE:0ISM
|
UK | €402.00 Million |
|
Dinhvu Port Investment Development JSC
VN:DVP
|
Vietnam | ₫97.30 Billion |
|
Kyeryong Const
KO:013580
|
Korea | ₩2.19 Trillion |
|
Itafos Inc
PINK:MBCF
|
USA | $383.35 Million |
|
Golden Ventures Leasehold Real Estate Investment Trust
BK:GVREIT
|
Thailand | ฿3.10 Billion |
|
Kudelski
SW:KUD
|
Switzerland | CHF228.06 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Ryvu Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ryvu Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ryvu Therapeutics SA (2010–2024)
The table below shows the annual total liabilities of Ryvu Therapeutics SA from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł234.89 Million | +63.56% |
| 2023-12-31 | zł143.61 Million | +9.14% |
| 2022-12-31 | zł131.59 Million | +121.55% |
| 2021-12-31 | zł59.39 Million | -17.42% |
| 2020-12-31 | zł71.92 Million | +13.92% |
| 2019-12-31 | zł63.13 Million | +3.77% |
| 2018-12-31 | zł60.84 Million | +53.72% |
| 2017-12-31 | zł39.58 Million | +18.46% |
| 2016-12-31 | zł33.41 Million | +81.95% |
| 2015-12-31 | zł18.36 Million | +4.63% |
| 2014-12-31 | zł17.55 Million | +18.19% |
| 2013-12-31 | zł14.85 Million | +51.28% |
| 2012-12-31 | zł9.82 Million | +62.45% |
| 2011-12-31 | zł6.04 Million | -31.08% |
| 2010-12-31 | zł8.77 Million | -- |